MedTrace Logo

Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male Adults

NCT04343547 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2020-04-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate drug-drug interaction by comparing the pharmacokinetics (PK)/pharmacodynamics (PD), safety, and tolerability of single/multiple doses of DWP16001 , DWC202001 and DWC202002 alone or in combination in healthy male adults.

Conditions

  • Healthy

Interventions

DRUG

DWP16001

Tablets, Oral, once daily single dose

DRUG

DWC202001+DWC202002

Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination

DRUG

DWP16001+DWC202001+DWC202002

Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04343547 on ClinicalTrials.gov